HC Wainwright Issues Pessimistic Estimate for PLX Earnings

Key Points

• HC Wainwright has revised its FY2025 earnings per share (EPS) estimate for Protalix BioTherapeutics from $0.14 to $0.05, reflecting a significant pessimistic outlook.
• Wall Street Zen downgraded Protalix BioTherapeutics from a "strong-buy" to a "buy" rating, although the stock still holds a consensus "Buy" rating with a target price of $15.00.
• Insider transactions showed Director Aharon Schwartz purchased 129,000 shares at $1.60 per share, increasing his ownership by 74.14% amid overall stock ownership of 6.50% by insiders.

Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Research analysts at HC Wainwright dropped their FY2025 EPS estimates for shares of Protalix BioTherapeutics in a research report issued on Monday, August 18th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.05 per share for the year, down from their previous forecast of $0.14. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share.

Separately, Wall Street Zen cut shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a report on Monday, May 12th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Protalix BioTherapeutics has a consensus rating of "Buy" and an average price target of $15.00.

Protalix BioTherapeutics Stock Performance

Protalix BioTherapeutics stock traded up $0.08 during midday trading on Wednesday, hitting $1.66. 690,192 shares of the company's stock were exchanged, compared to its average volume of 835,539. Protalix BioTherapeutics has a 12 month low of $0.89 and a 12 month high of $3.10. The company has a market cap of $132.36 million, a PE ratio of -12.77 and a beta of -0.21. The firm has a 50-day moving average of $1.49 and a two-hundred day moving average of $2.01.

Insider Transactions at Protalix BioTherapeutics

In other Protalix BioTherapeutics news, Director Aharon Schwartz purchased 129,000 shares of Protalix BioTherapeutics stock in a transaction on Tuesday, June 10th. The stock was bought at an average cost of $1.60 per share, with a total value of $206,400.00. Following the transaction, the director owned 303,000 shares of the company's stock, valued at $484,800. This represents a 74.14% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.50% of the company's stock.

Hedge Funds Weigh In On Protalix BioTherapeutics

A number of institutional investors have recently bought and sold shares of PLX. Cascade Financial Partners LLC purchased a new position in Protalix BioTherapeutics during the 2nd quarter worth approximately $25,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Protalix BioTherapeutics during the 2nd quarter worth approximately $27,000. Bank of America Corp DE raised its position in Protalix BioTherapeutics by 364,766.7% during the 2nd quarter. Bank of America Corp DE now owns 21,892 shares of the company's stock worth $32,000 after buying an additional 21,886 shares during the last quarter. NewEdge Advisors LLC purchased a new position in shares of Protalix BioTherapeutics during the 1st quarter valued at approximately $39,000. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Protalix BioTherapeutics during the 2nd quarter valued at approximately $40,000. 16.53% of the stock is owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.